SCHEMBL14745965

SCHEMBL14745965

COC(=O)c1c(O)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1ccc(N(C)C)cc1CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 6/20 0.39
TSHR P16473 2/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TP53 P04637 2/20 0.37
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
EDNRB P24530 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
TLR9 Q9NR96 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745744 0.98 EGLN1 (0.39) EGLN1TSHRMAPTALDH1A1HPGD
SCHEMBL14745574 0.93 EDNRB (0.41) EGLN1TSHRMAPTALDH1A1HPGD
SCHEMBL14745886 0.91 EDNRB (0.41) EGLN1TSHRALDH1A1POLBEDNRB
SCHEMBL14745862 0.89 EGLN1 (0.40) EGLN1TSHRMAPTALDH1A1HPGD
SCHEMBL14746276 0.87 EGLN1 (0.40) EGLN1TSHRMAPTALDH1A1HPGD
SCHEMBL14745682 0.85 GABRG2 (0.44) EGLN1TSHRMAPTALDH1A1HSD17B10
SCHEMBL14745792 0.83 GABRG2 (0.44) EGLN1TSHRMAPTALDH1A1HSD17B10
SCHEMBL14745818 0.81 KMT2A (0.39) EGLN1TSHRMAPTALDH1A1TP53
SCHEMBL14745710 0.81 EGLN1 (0.37) EGLN1TSHRMAPTALDH1A1HPGD
SCHEMBL17495015 0.80 MAPT (0.38) EGLN1TSHRMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EGLN1 712/4885TSHR 4837/4885MAPT 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.